WASHINGTON, DC--(Marketwired - Oct 11, 2016) - The Alliance for Regenerative Medicine (ARM), announced today the election of the 2017 ARM Officers, Executive Committee and Board of Directors.
"ARM leadership reflects the geographical and technological diversity of our membership," said Morrie Ruffin, managing director of ARM. "We welcome these new slates of officers, directors and executive committee members; each has demonstrated direct involvement and active participation in ARM's activities and has made vital contributions to the advancement of this sector."
ARM Officer terms are typically two years, while the ARM Board of Directors and Executive Committee are held to an annual re-election or rotation process, with nominations and approval by the ARM membership and Board.
ARM 2017 Officers:
- Robert Preti - Co-Founder & President, PCT, a Caladrius Company; Senior Vice President, Manufacturing & Technical Operations and Chief Technology Officer, Caladrius Biosciences (ARM Chairman)
- Matt Patterson - President & CEO, Audentes Therapeutics (ARM Vice Chairman)
- Martha Rook - Head of Gene Editing and Novel Modalities, MilliporeSigma / EMD Millipore (ARM Secretary)
- Rahul Aras - Co-Founder, President & CEO, Juventas Therapeutics (ARM Treasurer)
ARM 2017 Executive Committee:
- Rahul Aras - Co-Founder, President & CEO, Juventas Therapeutics (also ARM Treasurer)
- Eduardo Bravo - Managing Director & CEO, TiGenix
- Doug Doerfler - President & CEO, MaxCyte
- Karen Kozarsky - President, Vector Partners
- Edward Lanphier - Founder & Chairman, Sangamo BioSciences (ARM ex-officio)
- Tom Novak - Vice President, Strategic Partnerships, Cellular Dynamics International / FUJIFILM
- Matt Patterson - President & CEO, Audentes Therapeutics (also ARM Vice Chairman)
- Robert Preti - Co-Founder & President, PCT, a Caladrius Company; Senior Vice President, Manufacturing & Technical Operations and Chief Technology Officer, Caladrius Biosciences (also ARM Chairman)
- Martha Rook - Head of Gene Editing and Novel Modalities, MilliporeSigma / EMD Millipore (also ARM Secretary)
- Jay Siegel - Chief Biotechnology Officer and Head, Scientific Strategy & Policy, Johnson & Johnson
- David Smith - Vice President, Global Business Development, Lonza
- Alexander Vos - CEO, PharmaCell
ARM 2017 Board of Directors:
- Zami Aberman - Chairman & CEO, Pluristem Therapeutics
- Martin Andrews - Senior Vice President, GSK Rare Disease Unit Head, GSK
- Rahul Aras - Co-Founder, President & CEO, Juventas Therapeutics (also ARM Treasurer)
- Nessan Bermingham - CEO, President & Founder, Intellia Therapeutics
- Eduardo Bravo - Managing Director & CEO, TiGenix
- Olivier Danos - Senior Vice President, Cell and Gene Therapy, Biogen
- Deborah Dean - Executive Vice President and Chief Compliance Officer, MiMedx
- Doug Doerfler - President & CEO, MaxCyte
- Flagg Flanagan - Chairman & CEO, DiscGenics
- Christian Homsy - CEO, Celyad
- Andrea Hunt - Vice President, New Products TA Lead Gene Therapy, Neuroscience and Ophthalmology, Shire
- Dena Ladd - Executive Director, Missouri Cures
- Paul Laikind - President & CEO, ViaCyte
- Edward Lanphier - Founder and Chairman, Sangamo BioSciences (ARM ex-officio)
- Michael May - CEO, Centre for Commercialization of Regenerative Medicine
- Gregory Naeve - Head External R&D Innovation, ImmunoOncology & Rinat Labs, San Francisco Worldwide Research & Development, Pfizer
- Tim Oldham - CEO & Executive Director, Cell Therapies Pty Ltd
- Matt Patterson - President & CEO, Audentes Therapeutics (also ARM Vice Chairman)
- Robert Preti - Co-Founder & President, PCT, a Caladrius Company; Senior Vice President, Manufacturing & Technical Operations and Chief Technology Officer, Caladrius Biosciences (also ARM Chairman)
- Byung Geon ("BG") Rhee - President, Green Cross Holdings
- Isabelle Riviere - Director, Cell Therapy & Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
- Martha Rook - Head of Gene Editing and Novel Modalities, MilliporeSigma / EMD Millipore (also ARM Secretary)
- Jay Siegel - Chief Biotechnology Officer and Head, Scientific Strategy & Policy, Johnson & Johnson
- Donna Skerrett - Chief Medical Officer, Mesoblast Ltd
- David Smith - Vice President, Global Business Development, Lonza
- Keith Thompson - CEO, Cell & Gene Therapy Catapult
- Phil Vanek - General Manager, Cell Therapy Technologies, GE Healthcare Life Sciences
- Alexander Vos - CEO, PharmaCell
- Jeffrey Walsh - Chief Financial and Strategy Officer, bluebird bio
- Sue Washer - President & CEO, AGTC
- Jason Wertheim - Assistant Professor of Surgery - Organ Transplantation, Department of Surgery, Institute for BioNanotechnology in Medicine, Feinberg School of Medicine and Chemistry of Life Processes Institute, Northwestern University
- Claudia Zylberberg - Founder & CEO, Akron Biotech
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 250 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org .
The Alliance for Regenerative Medicine Lyndsey Scull 202 213 7086 lscull@alliancerm.org
